Hologic, Inc. (HOLX) Return on Invested Capital (ROIC): 7.35%
Is Hologic, Inc.’s return on invested capital (ROIC) high or low?
Hologic, Inc.'s return on invested capital (ROIC) of 7.35% is 46% below its 5-year average of 13.56%, near the low end of its 5-year range (5.47%–24.75%).
The return on invested capital (ROIC) for Hologic, Inc. (HOLX) is 7.35% as of Wednesday, June 10, 2026. It is below its 12-month average by 14.49% (8.59%).
HOLX Return on Invested Capital (ROIC) Chart
HOLX Average Return on Invested Capital (ROIC) Chart
HOLX Current vs Average Return on Invested Capital (ROIC) Chart
HOLX Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
7.35%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
8.59%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
9.78%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
13.56%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
9.47%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
6.39%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
4.22%
CURRENT VS TTM AVG
-14.49%
CURRENT VS 3Y AVG
-24.83%
CURRENT VS 5Y AVG
-45.81%
CURRENT VS 10Y AVG
-22.42%
CURRENT VS 15Y AVG
+15.08%
CURRENT VS 20Y AVG
+74.35%
HOLX Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hologic, Inc. (HOLX) | — | 7.35% | 8.59% | 9.78% | 13.56% |
| Moderna, Inc. (MRNA) | $18.40B | -29.70% | -31.12% | -12.69% | 0.19% |
| Align Technology, Inc. (ALGN) | $12.56B | 9.94% | 9.96% | 10.13% | 11.66% |
| BioNTech SE (BNTX) | $21.81B | -3.14% | -4.79% | 9.55% | 20.42% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 35.46% | 38.26% | 37.51% | 36.01% |
| Waters Corporation (WAT) | $23.83B | 17.57% | 18.00% | 20.73% | 22.79% |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 8.36% | 4.65% | 6.09% | 6.66% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 2.04% | 2.21% | 2.35% | 2.39% |
| Veeva Systems Inc. (VEEV) | $27.37B | 9.48% | 9.25% | 9.54% | 11.31% |
| Hims & Hers Health, Inc. (HIMS) | $6.42B | 6.02% | 9.35% | -2.77% | -9.72% |
Capital Efficiency
ROIC
7.3%
ROE
10.4%
Hologic, Inc. Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Hologic, Inc. Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Hologic, Inc. (HOLX)?
- The return on invested capital (ROIC) for HOLX stock is 7.35%.
- Is Hologic, Inc.'s return on invested capital (ROIC) high or low?
- Hologic, Inc.'s return on invested capital (ROIC) of 7.35% is 46% below its 5-year average of 13.56%, near the low end of its 5-year range (5.47%–24.75%).
- What is the TTM average return on invested capital (ROIC) for Hologic, Inc. (HOLX)?
- The TTM average return on invested capital (ROIC) for HOLX stock is 8.59%.
- What is the 3Y average return on invested capital (ROIC) for Hologic, Inc. (HOLX)?
- The 3Y average return on invested capital (ROIC) for HOLX stock is 9.78%.
- What is the 5Y average return on invested capital (ROIC) for Hologic, Inc. (HOLX)?
- The 5Y average return on invested capital (ROIC) for HOLX stock is 13.56%.
- What is the 10Y average return on invested capital (ROIC) for Hologic, Inc. (HOLX)?
- The 10Y average return on invested capital (ROIC) for HOLX stock is 9.47%.
- What is the 15Y average return on invested capital (ROIC) for Hologic, Inc. (HOLX)?
- The 15Y average return on invested capital (ROIC) for HOLX stock is 6.39%.
- What is the 20Y average return on invested capital (ROIC) for Hologic, Inc. (HOLX)?
- The 20Y average return on invested capital (ROIC) for HOLX stock is 4.22%.
Hologic, Inc. Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-09-27 | 7.35% |
| 2024-09-30 | 9.84% |
| 2023-09-30 | 5.47% |
| 2022-09-30 | 16.45% |
| 2021-09-30 | 24.75% |
| 2020-09-30 | 17.52% |
| 2019-09-30 | 0.98% |
| 2018-09-30 | -0.98% |
| 2017-09-30 | 11.58% |
| 2016-09-30 | 6.51% |
| 2015-09-30 | 4.75% |
| 2014-09-30 | 1.27% |
| 2013-09-30 | -10.51% |
| 2012-09-30 | 1.15% |
| 2011-09-30 | 4.71% |
| 2010-09-30 | 1.35% |
| 2009-09-30 | -37.35% |
| 2008-09-30 | -2.52% |
| 2007-09-30 | 10.58% |
| 2006-09-30 | 3.51% |
| 2005-09-30 | 12.12% |
| 2004-09-30 | 7.08% |
| 2003-09-30 | 1.90% |
| 2002-09-30 | -1.06% |
| 2001-09-30 | -13.18% |
| 2000-09-30 | -11.18% |
| 1999-09-30 | -4.04% |
| 1998-09-30 | 4.81% |
| 1997-09-30 | 11.36% |
| 1996-09-30 | 7.35% |
Related Metrics
About Hologic, Inc.
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Paul Malenchini